Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer A Prospective, Open-label, Multicenter, Phase II Trial
Latest Information Update: 22 Oct 2024
At a glance
- Drugs SHR A2102 (Primary) ; SHR-A1921 (Primary) ; SHR-A2009 (Primary) ; Trastuzumab rezetecan (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 22 Oct 2024 New trial record